BHVN
Biohaven Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Biohaven has 10 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceIn February 2022, we announced that we entered into a definitive agreement with Channel Biosciences, LLC, a subsidiary of Knopp Biosciences, LLC, to acquire a drug discovery platform targeting Kv7 ion channels, adding the latest advances in ion channel modulation to our growing neuroscience portfolio.
BHVN 10-Kaccession 0001935979-26-000020
SentenceBased on the early results for BHV-1510, we entered into an expanded collaboration agreement with GeneQuantum Healthcare Co. Ltd. ("GeneQuantum"), which provides broad target exclusivity for up to 18 ADC targets incorporating the TopoIx payload.
BHVN 10-Kaccession 0001935979-26-000020
SentenceIn March 2023, we entered into an exclusive, worldwide (excluding China and its territories and possessions) license agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll") (the "Highlightll Agreement"), pursuant to which we obtained the right to research, develop, manufacture and commercialize Highlightll's brain penetrant dual TYK2/JAK1 inhibitor program.
BHVN 10-Kaccession 0001935979-26-000020
SentenceIn January 2022, we entered into an agreement with KU Leuven ("the KU Leuven Agreement") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders.
BHVN 10-Kaccession 0001935979-26-000020
SentenceIn January 2025, Biohaven announced a research collaboration and license agreement with Merus N.V. ("Merus") to co-develop three novel dual-targeting ADCs, leveraging Merus' Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies (the "Merus Agreement").
BHVN 10-Kaccession 0001935979-26-000020
SentenceIn January 2021, we entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel MoDE platform.
BHVN 10-Kaccession 0001935979-26-000020
SentenceIn addition, we announced that we entered into an agreement with Ypsomed to develop and manufacture BHV-1300 in an easy-to-use, autoinjector for self-administration intended for commercialization.
BHVN 10-Kaccession 0001935979-26-000020
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−6.49%
vs ±14.7% implied · ×0.44
shaded = implied · ▲▼ = realized
Biohaven Ltd.
15.44
—
Linked news
Expected move
Inputsspot 15.42exp Mar 19ATM strike 15ATM straddle 7.50IV 102%